Peptide receptor radionuclide therapy of Merkel cell carcinoma using 177lutetium-labeled somatostatin analogs in combination with radiosensitizing chemotherapy: A potential novel treatment based on molecular pathology

Annals of Nuclear Medicine

Volumn 26, Issue 4, 2012, Pages 365-369

  Salavati, Ali ^a   Prasad, Vikas ^a   Schneider, Claus Peter ^b   Herbst, Rudolf ^c   Baum, Richard Paul ^a  

^a ZENTRALKLINIK BAD BERKA   (Germany)

^b Department of Oncology ^*  (Germany)

^c HELIOS KLINIKUM ERFURT   (Germany)

Author keywords

68Ga somatostatin receptor PET CT; Merkel cell carcinoma; Peptide receptor radionuclide therapy; Synchronous chemo radiation therapy

Indexed keywords

1, 4, 7, 10 TETRAAZACYCLODODECANE 1, 4, 7, 10 TETRAACETIC ACID 1 DEXTRO PHENYLALANINE 1 TYROSINE 3 THREONINE 8 OCTREOTIDE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; GALLIUM 68; LUTETIUM 177; RADIOSENSITIZING AGENT; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG;

ADJUVANT CHEMORADIOTHERAPY; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; ERYTHROPENIA; FOLLOW UP; HUMAN; MALE; MERKEL CELL TUMOR; MOLECULAR PATHOLOGY; MULTIPLE CYCLE TREATMENT; PEPTIDE RECEPTOR RADIONUCLIDE TEHRAPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOSENSITIZATION; TREATMENT RESPONSE;

CARCINOMA, MERKEL CELL; COMBINED MODALITY THERAPY; HUMANS; ISOTOPE LABELING; LUTETIUM; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RADIATION-SENSITIZING AGENTS; RADIOISOTOPES; RECEPTORS, PEPTIDE; SKIN NEOPLASMS; SOMATOSTATIN;

EID: 84862702776     PISSN: 09147187     EISSN: 18646433     Source Type: Journal    
DOI: 10.1007/s12149-012-0578-3     Document Type: Article

References (20)

1. Poulsen M, Rischin D, Walpole E, Harvey J, Mackintosh J, Ainslie J, et al. High-risk Merkel cell carcinoma of the skin treated with synchronous carboplatin/etoposide and radiation: a Trans-Tasman Radiation Oncology Group Study-TROG 96:07. J Clin Oncol. 2003;21(23):4371-6. (Pubitemid 46621814)
2. Rockville Merkel Cell Carcinoma Group. Merkel cell carcinoma: recent progress and current priorities on etiology, pathogenesis, and clinical management. J Clin Oncol. 2009;27(24):4021-6.
3. Allen PJ, Bowne WB, Jaques DP, Brennan MF, Busam K, Coit DG. Merkel cell carcinoma: prognosis and treatment of patients from a single institution. J Clin Oncol. 2005;23(10):2300-9. (Pubitemid 46218722)
4. Lemos BD, Storer BE, Iyer JG, Phillips JL, Bichakjian CK, Fang LC, et al. Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system. J Am Acad Dermatol. 2010;63(5):751-61.
5. Wobser M, Kurzinger N, Ugurel S, Brocker EB, Becker JC. Therapy of metastasized Merkel cell carcinoma with liposomal doxorubicin in combination with radiotherapy. J Dtsch Dermatol Ges. 2009;7(6):521-5.
6. Jouary T, Lalanne N, Siberchicot F, Ricard AS, Versapuech J, Lepreux S, et al. Neoadjuvant polychemotherapy in locally advanced Merkel cell carcinoma. Nat Rev Clin Oncol. 2009;6(9): 544-8.
7. Garneski KM, Nghiem P. Merkel cell carcinoma adjuvant therapy: current data support radiation but not chemotherapy. J Am Acad Dermatol. 2007;57(1):166-9. (Pubitemid 46899275)
8. Tai PT, Yu E, Winquist E, Hammond A, Stitt L, Tonita J, et al. Chemotherapy in neuroendocrine/Merkel cell carcinoma of the skin: case series and review of 204 cases. J Clin Oncol. 2000; 18(12):2493-9. (Pubitemid 30415837)
9. van Essen M, Krenning EP, Kam BL, de Herder WW, van Aken MO, Kwekkeboom DJ. Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2008;35(4): 743-8.
10. Wong JY, Shibata S, Williams LE, Kwok CS, Liu A, Chu DZ, et al. A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer. Clin Cancer Res. 2003;9(16 Pt 1): 5842-52. (Pubitemid 38018066)
11. Prasad V, Baum RP. Biodistribution of the Ga-68 labeled somatostatin analogue DOTA-NOC in patients with neuroendocrine tumors: characterization of uptake in normal organs and tumor lesions. Q J Nucl Med Mol Imaging. 2010;54(1):61-7.
12. Virgolini I, Ambrosini V, Bomanji JB, Baum RP, Fanti S, Gabriel M, et al. Procedure guidelines for PET/CT tumour imaging with 68 Ga-DOTA-conjugated peptides: 68 Ga-DOTA-TOC, 68 Ga-DOTA-NOC, 68 Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2010;37(10):2004-10.
13. Kaemmerer D, Peter L, Lupp A, Schulz S, Sanger J, Prasad V, et al. Molecular imaging with Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2011;38(9): 1659-68.
14. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26(13):2124-30.
15. Hagtvet E, Roe K, Olsen DR. Liposomal doxorubicin improves radiotherapy response in hypoxic prostate cancer xenografts. Radiat Oncol. 2011;6:135.
16. Sharkey RM, Hajjar G, Yeldell D, Brenner A, Burton J, Rubin A, et al. A phase I trial combining high-dose 90Y-labeled humanized anti-CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancer. J Nucl Med. 2005;46(4):620-33. (Pubitemid 41716407)
17. Costantini DL, Villani DF, Vallis KA, Reilly RM. Methotrexate, paclitaxel, and doxorubicin radiosensitize HER2-amplified human breast cancer cells to the Auger electron-emitting radiotherapeutic agent (111)In-NLS- trastuzumab. J Nucl Med. 2010;51(3): 477-83.
18. Bonner JA, Lawrence TS. Doxorubicin decreases the repair of radiation-induced DNA damage. Int J Radiat Biol. 1990;57(1): 55-64. (Pubitemid 20027031)
19. Pauwels B, Wouters A, Peeters M, Vermorken JB, Lardon F. Role of cell cycle perturbations in the combination therapy of chemotherapeutic agents and radiation. Future Oncol. 2010;6(9): 1485-96.
20. Supiot S, Gouard S, Charrier J, Apostolidis C, Chatal JF, Barbet J, et al. Mechanisms of cell sensitization to alpha radioimmunotherapy by doxorubicin or paclitaxel in multiple myeloma cell lines. Clin Cancer Res. 2005;11(19 Pt 2):7047s-52s. (Pubitemid 41428703)